The Horizon Playbook: Tim Walbert Takes the Reins at Crystalys Therapeutics

SAN DIEGO, CA – September 23, 2026 — When Amgen acquired Horizon Therapeutics for $28.3 billion in 2023, it validated a masterclass in biopharmaceutical commercialization orchestrated by Horizon's longtime CEO, Tim Walbert. A cornerstone of that multi-billion-dollar valuation was Krystexxa, a refractory gout treatment that Horizon transformed into a blockbuster biologic. Now, Walbert is returning to the gout arena.

Crystalys Therapeutics, a clinical-stage biopharmaceutical company focused on advanced gout treatments, announced today that Walbert has been named Chairman of the Board. After serving as an independent director since January 2026, Walbert takes the helm at a critical inflection point as the company advances its lead candidate, dotinurad, through a global Phase 3 registrational program.

The leadership expansion does not stop there. Seth H.Z. Fischer, a 29-year Johnson & Johnson veteran and former CEO of Vivus, has joined the Board of Directors representing lead founding investor Catalys Pacific. Simultaneously, company co-founder DeAnne Reid has been promoted to Chief Administrative Officer to scale operations, while founding Executive Chairman Dr. BT Slingsby transitions to a Board Observer role.

"We are building Crystalys for the next stage of our growth, and Tim, Seth and DeAnne bring the leadership and experience that will support dotinurad as it advances through our registrational program," said James M. Mackay, Ph.D., Co-Founder, Chief Executive Officer and President of Crystalys Therapeutics. "Tim has an exceptional track record of building and leading successful biopharmaceutical companies, including bringing important new therapies to people living with gout."

Closing the Gout Care Gap

Gout is the most common form of inflammatory arthritis, afflicting over 10 million individuals in the United States alone. Characterized by hyperuricemia—an excess of uric acid in the blood—the disease leads to painful urate crystal deposition, recurrent flares, and severe joint damage. Despite its prevalence, the treatment paradigm has remained stubbornly stagnant.

First-line therapy typically relies on generic xanthine oxidase inhibitors (XOIs) like allopurinol. However, due to fears of renal impairment and severe cutaneous adverse reactions, allopurinol is frequently underdosed in real-world practice, leaving 40% to 50% of patients failing to achieve target serum uric acid (sUA) levels below 6.0 mg/dL. Second-line alternatives are similarly fraught: febuxostat carries an FDA Black Box Warning for cardiovascular death risks, and probenecid poses a high risk of kidney stones. For patients who exhaust these options, the only remaining alternative is the third-line biologic Krystexxa—an intravenous infusion costing upwards of $300,000 annually.

Crystalys aims to position dotinurad as the missing oral bridge in this treatment gap. Dotinurad is a selective urate reabsorption inhibitor (SURI) that targets the URAT1 transporter to increase renal uric acid excretion.

Historically, URAT1 inhibitors have faced severe clinical hurdles. A decade ago, AstraZeneca's lesinurad was derailed by acute kidney injury and a subsequent Black Box Warning because it weakly inhibited URAT1 while also inadvertently blocking renal organic anion transporters (OAT1 and OAT3). Dotinurad appears to have overcome this polypharmacology trap. Structural studies indicate it binds selectively to unique extracellular residues on URAT1, making it more than 800 times more potent than lesinurad without triggering off-target renal secretory crashes.

"Gout is the most common form of inflammatory arthritis, yet a significant treatment gap remains for patients who are not adequately controlled on or cannot tolerate first-line therapy," noted Walbert in today's announcement. "I believe dotinurad has the potential to close that gap, and Crystalys has assembled the clinical program, team and resources to evaluate it rigorously."

De-Risking the Second Line: An Asian Success Story

What makes Crystalys an anomaly in the high-attrition landscape of late-stage biotech is that dotinurad is not an unproven chemical entity. The drug was originally discovered by Japan's Fuji Yakuhin and has been approved by the Japan Pharmaceuticals and Medical Devices Agency since 2020. Marketed as Urece, and recently approved in China via a partnership with Eisai, dotinurad has already accumulated over 2.2 million patient-years of real-world human safety and efficacy data across Asia.

This transpacific de-risking strategy is a hallmark of Catalys Pacific, the investment firm that helped launch the biopharmaceutical firm. By licensing an asset with a proven commercial and safety track record in the East, Crystalys can bypass much of the early-stage clinical anxiety that plagues Western drug development.

The company is currently executing the JEWEL Clinical Program to secure FDA and EMA approvals. The program includes two massive Phase 3 global trials, RUBY and TOPAZ, which launched dosing in October 2025. RUBY is evaluating approximately 500 patients over 64 weeks, comparing dotinurad head-to-head against allopurinol. TOPAZ is targeting 250 patients with visible tophaceous gout over 76 weeks to measure tophus burden reduction. Additionally, a Phase 2 trial named AMETHYST is evaluating the drug in patients who are explicitly intolerant to XOIs or who have failed uricase therapy.

"Across my career bringing medicines to patients, I have seen how much a strong therapeutic opportunity benefits from disciplined development and thoughtful commercial planning," said Fischer. "Crystalys has made impressive progress advancing a differentiated urate transporter 1 (URAT1) inhibitor, one already supported by years of clinical use in approved markets, into a comprehensive registrational program in the United States and Europe."

The Strategic Endgame

The appointments of Walbert, Fischer, and Reid signal a deliberate pivot from clinical development to aggressive corporate strategy. Walbert's history of scaling distressed or under-optimized assets into multi-billion-dollar franchises aligns perfectly with the market dynamics surrounding gout today.

The hyperuricemia sector has seen a surge in dealmaking activity. Earlier in 2026, Swedish Orphan Biovitrum acquired Arthrosi Therapeutics—and its competing URAT1 inhibitor pozdeutinurad—for $950 million upfront and up to $550 million in milestones. While pozdeutinurad leads dotinurad in Western clinical execution by roughly 18 to 24 months, industry insiders are quick to point out that dotinurad's massive trove of Japanese post-marketing data provides a safety moat that unapproved new chemical entities lack.

With a war chest of approximately $335 million in committed capital from its Series A and Series B rounds led by Frazier Life Sciences, Crystalys boasts a cash runway that extends through mid-2029. This financial stability comfortably covers the anticipated early 2028 data readouts for the RUBY and TOPAZ trials.

For biotech analysts monitoring the space, the strategic intent is clear. The assembly of this specific executive bench suggests the firm is preparing for one of two lucrative outcomes: a standalone initial public offering to fund an independent U.S. and European commercial launch, or a high-premium acquisition by a large pharmaceutical player seeking to dominate the metabolic and inflammatory disease markets.

As Dr. Mackay noted regarding the transition of the founding Chairman, "BT's vision and leadership have been instrumental in taking Crystalys from its founding to the global late-stage company it is today. We are grateful for his contributions as Chairman and pleased that we will continue to benefit from his perspective and counsel."

With the foundational science de-risked and a heavyweight leadership team now formally in place, Crystalys Therapeutics is no longer just a clinical-stage hopeful. It is a highly calculated commercial enterprise, executing a playbook that its new Chairman has already proven can yield billion-dollar results.